Skip to content
Get BIO’s view on everything from health care to biofuels and the bioeconomy. The below articles include BIO statements, opinion, and calls to action, as well as articles and op-eds written by BIO leadership.
With health care affordability a top concern for many Americans, pharmacy benefit managers (PBMs) continue to stand at the center of the debate. Working […]
The hidden layer of PBMs: What a recent investigation reveals Read More »
Americans are frustrated with the health care system for two reasons. First, it costs too much. But—second—it provides too little. While most of the
Nearly half of Americans say insurers’ rules on access delayed, denied, or altered care Read More »
In an initiative to accelerate capital formation for biotech innovation, the Biotechnology Innovation Organization (BIO) on Jan. 7 launched the BIO Investment Council (BIC),
BIO Investment Council will bring together VC and small biotechs to boost innovation Read More »
The Biotechnology Innovation Organization (BIO) warned that new changes in federal recommendations for the childhood vaccination schedule are unscientific and put children’s health at
BIO warns of risks from change to CDC’s vaccine recommendations Read More »
Legislation to free up capital for small innovative firms by removing regulatory barriers for both companies and investors passed the House Dec. 11—a move
House passes BIO-backed legislation to increase access to capital Read More »
Historically, Charlotte has been recognized as a major U.S. financial hub. Now, the city is making significant strides in another transformative sector: health care
Charlotte emerging as a global leader in health care innovation and med tech Read More »
Cancer patients are suffering serious health consequences because step therapy practices enforced by pharmacy benefit managers (PBMs) are preventing timely access to essential medicines,
Oncologist warns PBM step therapy has ‘crossed a dangerous line’ Read More »
European countries don’t just pull prices for medicines out of thin air. The prices that those governments set are based on specific sets of
It is often taken as a given that drug prices in the U.S. are higher than those in other nations. And while there is
Putting Americans First: International prices in context Read More »
The most notable differences between the pharmaceutical market in the U.S. and those in other countries are not in the prices. They’re in the
